Omega-3s and Mental Health: New Supplement Protocols for Anxiety and Depression

Could Omega-3 supplements complement traditional treatments for anxiety and depression? The possibility is plausible; studies suggest cases where real benefits could be achieved, and there are even some proposed treatment guidelines. Let's explore possible supplementation protocols based on scientific evidence.

In recent decades, the link between nutrition and mental health has evolved from a fringe hypothesis to a fully-fledged field of research. Among the nutrients most studied for their potential role in promoting mental well-being are omega-3 fatty acids, particularly those of marine origin, namely EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).

An interesting field of application is the prevention and management of anxiety and depression. What does the available data say? Do Omega-3s work? In what cases? Does it make sense to discuss supplementation protocols?

To answer these questions, it is necessary to distinguish between biological hypotheses, clinical findings, and official recommendations.

Omega-3 for Anxiety and Depression: The Biological Hypothesis

Anxiety and depression have a multifactorial origin. The underlying mechanisms include:

• chronic low-grade neuroinflammation, with an increase in pro-inflammatory molecules, such as the cytokines interleukin-6 (IL-6) and Tumor Necrosis Factor α (TNF-α), and in an important inflammation marker, C-reactive protein (CRP);
• alterations in neuronal plasticity, a property potentially relevant for emotional adaptation;
• reduction of Brain-Derived Neutrophic Factor (BDNF), a factor which, if present at normal levels, promotes adaptation to stress;
• dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, which is persistently activated by chronic stress;
• Interactions between the gut, microbiota, and brain in the so-called gut-brain axis; in particular, alterations in the balance of intestinal flora (dysbiosis) can increase intestinal permeability, promoting increased systemic inflammation, and alter the production of neurotransmitters involved in mood regulation (such as gamma-aminobutyric acid (GABA), which promotes relaxation by reducing neuronal excitability, and serotonin—aptly known as the "happiness hormone").
  

So, from a biological point of view, Omega 3 could counteract anxiety and depression thanks to:

• to their anti-inflammatory properties;
• to their structural role in neuronal membranes. In particular, DHA is the most abundant fatty acid in the brain and is considered a fundamental ally in its development and function.
  

Furthermore, scientific literature suggests that EPA and DHA may influence BDNF and neuronal plasticity and regulate the HPA axis and blood levels of cortisol, the stress molecule par excellence.

Are Omega-3s Really Effective Against Mood Disorders? What Clinical Studies Say

Starting from this biologically plausible hypothesis, several studies have field-tested the potential of Omega-3s against mood disorders. Reviews and meta-analyses of available clinical studies suggest different efficacy depending on whether the goal is to manage anxiety or depression.

In the case of anxiety, a systematic review published in 2024 in BMC Psychiatry indicates that omega-3 supplements may help improve symptoms without significant adverse effects.

The analysis included 23 clinical studies, involving a total of 2,189 people. Significant effects were associated with doses of at least 2 grams per day; unfortunately, however, differences in research methodologies adopted in individual studies and in the characteristics of the populations involved prevented the authors from drawing clear, definitive conclusions on the efficacy of Omega-3s against anxiety.

Previously, a meta-analysis published in 2018 in JAMA Network Open also highlighted the need for a daily intake of at least 2 grams of omega-3s to reduce anxiety symptoms; furthermore, this analysis suggests the need to personalize supplementation, indicating that those with underlying medical conditions, such as psychiatric disorders, may benefit most from taking these nutrients.

In the case of depression, the available data are more consistent and allow us to draw clearer conclusions.

On the one hand, omega-3s don't appear to effectively prevent the onset of depression. On the other hand, one of the most recent reviews of the scientific literature suggests they may improve symptoms in people who have already been diagnosed.

Published in Translational Psychiatry in 2019, this review included 26 randomized controlled clinical trials involving a total of 2,160 individuals, concluding that benefits may emerge especially when omega-3s are consumed primarily in the form of EPA. Consuming only DHA, however, would not be an effective option.

The effects would be evident at dosages even lower than 1 gram of EPA per day and significant clinical improvements would be obtained with formulations composed of at least 60% EPA.

Even more recently, in 2024, a narrative review published in Current Opinion in Clinical Nutrition and Metabolic Care confirmed symptom improvement in patients with major depressive disorder (a severe form of depression), highlighting a more consistent effect in patients with high levels of inflammation or other comorbid conditions. In this analysis, however, EPA doses above 1 gram appeared to be effective.

Possible integrative protocols against anxiety

Currently, there are no Italian guidelines that explicitly address Omega-3 in relation to anxiety and depression. However, both the CREA (Council for Agricultural Research and Analysis of Agricultural Economics) and the Italian Society of Human Nutrition (SINU) recommend including 2-3 servings of fish in the weekly diet, favoring variety and oily fish , which are rich in Omega-3 EPA and DHA.

In the specific case of anxiety, there are not even official clinical guidelines from international scientific societies that recommend a standardized protocol for Omega 3 intake.

The American Psychiatric Association, however, provides general guidance according to which the management of some mood disorders may also be supported by taking 1 gram of combined EPA and DHA daily.

However, many of the studies with positive results on anxiety used total doses of Omega 3 in the order of about 2 grams per day and according to some analyses, going below this dosage could lead to non-significant results.

The optimal EPA:DHA ratio is unclear; some data suggest that EPA may be more important, but the evidence for this superiority is more consolidated in the case of depression and not specific to anxiety.

In clinical studies, supplementation has been continued for 8-12 weeks or longer, but even when it comes to establishing a minimum supplementation duration, there is no uniform protocol. Rather, a dose-response effect has been observed, suggesting that the duration and dosage of supplementation should be considered together to assess the impact on anxiety symptoms.

Generally speaking, if used as a complementary approach, Omega-3 supplementation may be beneficial at doses of approximately 2 grams per day of EPA+DHA, lasting at least several weeks. Furthermore, those with complex diagnoses or medical conditions may particularly benefit from supplementation.

Possible integrative protocols against depression

In the case of depression, however, the International Society for Nutritional Psychiatry Research has proposed clinical guidelines for the use of Omega 3 as an adjunct in the treatment of major depression.

The recommended formulations are pure EPA or a ratio greater than 2:1 with DHA; the suggested dosage, however, is 1-2 grams net of EPA per day. Omega-3s should be taken in addition to antidepressant therapy or other clinical treatments, and not as a replacement, with the aim of enhancing their antidepressant effect.

These guidelines are supported by suggestions from clinical studies, according to which:

• effective supplements are those based on long-chain Omega 3 (EPA and DHA), such as those produced with fish oil;
• Between EPA and DHA, EPA may be more useful for managing depression.
  

The minimum duration of intake supported by clinical studies is 8-12 weeks, during which it is preferable to take:

• a high EPA supplement, or
• an EPA+DHA supplement, but with EPA predominant.
  

When supplementation is used alongside standard antidepressant therapy, the benefits may be greater; in any case, clinical monitoring by a physician or psychiatrist is necessary.

Why are EPA and DHA not equivalent?

In light of what has been said, it appears clear that a crucial point – and, at least apparently, often overlooked – is that not all Omega 3s are the same.

EPA and DHA are the two main biologically active forms, but while EPA is more directly involved in modulating inflammation and immune signaling, DHA is essential for the structure of neuronal membranes but less active on an anti-inflammatory level.

This distinction becomes central when analyzing the results of clinical studies and may help explain why, in practice, EPA and DHA appear not to be equivalent.

Omega 3 for Anxiety and Depression: A Message from Science

The evidence currently available suggests that, although there is no standard protocol shared by industry authorities, Omega 3s should be considered nutrients that promote good health and could also support psychological or pharmacological therapies for anxiety and depression.

Furthermore, it clearly emerges that Omega 3:

• they should not be considered primary treatment for anxiety disorders and depression;
• They are not recommended as a substitute for psychotherapeutic or pharmacological treatments, but can be used alongside them.
  

Bibliographic references:

Bafkar N, Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. Efficacy and safety of omega-3 fatty acids supplementation for anxiety symptoms: a systematic review and dose-response meta-analysis of randomized controlled trials. BMC Psychiatry. 2024 Jun 18;24(1):455. doi: 10.1186/s12888-024-05881-2

Dyall SC, Malau IA, Su KP. Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials. Curr Opin Clin Nutr Metab Care. 2025 Mar 1;28(2):66-74. doi: 10.1097/MCO.0000000000001077

Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, Fan B, Lu C, McIntyre RS. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry. 2019 Aug 5;9(1):190. doi: 10.1038/s41398-019-0515-5. Erratum in: Transl Psychiatry. 2021 Sep 7;11(1):465. doi: 10.1038/s41398-021-01582-6

Su KP, Tseng PT, Lin PY, Okubo R, Chen TY, Chen YW, Matsuoka YJ. Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018 Sep 7;1(5):e182327. doi: 10.1001/jamanetworkopen.2018.2327